Evidence map›Paper›PMID 42553192›Full record

ArticleGut microbiome (Cambridge, England)2026

Exploring the prebiotic potential of commercial cellobiose: a randomized, controlled trial.

Manxi Huang, Peter Philip James Jackson, Afroditi Chatzifragkou, Robert Adrian Rastall

Abstract read
In one paragraph

Article in Gut microbiome (Cambridge, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Manxi HuangFood and Nutritional Sciences, University of Reading, UK.ORCID https://orcid.org/0009-0005-7448-2393
Peter Philip James JacksonDepartment of Food Science, Purdue University, USA.
Afroditi ChatzifragkouFood and Nutritional Sciences, University of Reading, UK.
Robert Adrian RastallFood and Nutritional Sciences, University of Reading, UK.ORCID https://orcid.org/0000-0003-1775-5226

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cellobiose, a β-(1 → 4)-linked disaccharide indigestible by humans, is a novel candidate prebiotic. Evidence from controlled human trials on its effects on the gut microbiota and metabolites remains limited. We conducted an exploratory randomised, double-blind, placebo-controlled trial in 37 healthy adults. Participants were allocated to three arms for 4 weeks, received 5 g/day and 10 g/day for cellobiose, oligofructose P95, or maltodextrin placebo. The primary endpoint was change in absolute abundance of

Indexed as

cellobiosedietary intervention trialgut microbiomeprebioticquantitative microbiome profiling

Identifiers

PMID42553192
PMCPMC13433336

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.